Javier E. Oesterheld
Experienced in Sickle Cell Disease

Dr. Javier E. Oesterheld

Hematology | Oncology
1001 Blythe Blvd., Suite 3000, 
Charlotte, NC 
On Staff At
Clinical Trials:Currently Recruiting for 6 Trials
Accepting New Patients
Offers Telehealth
24 Years of Experience
Experienced in Sickle Cell Disease
1001 Blythe Blvd., Suite 3000, 
Charlotte, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Javier Oesterheld is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Oesterheld has been practicing medicine for over 24 years and is rated as an Experienced provider by MediFind in the treatment of Sickle Cell Disease. His top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Ewing Sarcoma, Osteosarcoma, and Bone Marrow Transplant. Dr. Oesterheld is currently accepting new patients.

His clinical research consists of co-authoring 20 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Universidad Central Del Caribe, 2001, 2001
Residency
University of Medicine & Dentistry of New Jersey, Pediatrics, 2004
Specialties
Hematology
Oncology
Licenses
Pediatrics in NC
Board Certifications
American Board Of Pediatrics, Pediatric Hematology And Oncology
American Board Of Pediatrics
Fellowships
New York-Presbyterian/Columbia University Medical Center, Pediatric Hematology/Oncology, 2007
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 1 Less Insurance Carrier -

Locations

Atrium Health Levine Children’s Cancer & Blood Disorders, a facility of Carolinas Medical Center
1001 Blythe Blvd., Suite 3000, Charlotte, NC 28203
Other Locations
Levine Children's Hospital
1000 Blythe Blvd., Charlotte, NC 28203

Additional Areas of Focus

Dr. Oesterheld has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Brain Tumor
Sickle Cell Disease
Anemia
Neuroblastoma
Leukemia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Eflornithine
Study Phase: Phase 2
PEACH TRIAL- Precision mEdicine and Adoptive Cellular tHerapy for the Treatment of Recurrent Neuroblastoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
PEACH TRIAL- Precision mEdicine and Adoptive Cellular tHerapy for the Treatment of Recurrent Neuroblastoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Biological
Study Drug: Tumor-Specific Ex Vivo Expanded Autologous Lymphocyte Transfer (TTRNA-xALT)
Study Phase: Phase 1
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Difluoromethylornithine (DFMO)
Study Phase: Phase 2
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma
Enrollment Status: Recruiting
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Ceritinib, Dasatinib, Sorafenib, Vorinostat, DFMO
Study Phase: Phase 2
Specimen Banking With Clinical and Genomic Data Registry With the Establishment of Tumor Models for Pediatric Cancers
Specimen Banking With Clinical and Genomic Data Registry With the Establishment of Tumor Models for Pediatric Cancers
Enrollment Status: Recruiting
Publish Date: June 13, 2025
Intervention Type: Other
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
Enrollment Status: Recruiting
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Difluoromethylornithine
Study Phase: Phase 2
Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drugs: Nab-Paclitaxel, Gemcitabine
Study Phase: Phase 2
An Intermediate Expanded Use Trial of DFMO
An Intermediate Expanded Use Trial of DFMO
Enrollment Status: Available
Publish Date: August 07, 2025
Intervention Type: Drug
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: August 05, 2025
Intervention Type: Drug, Procedure
Study Drugs: Nivolumab, Azacitidine
Study Phase: Phase 1
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Enrollment Status: Completed
Publish Date: August 06, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase I Trial of Tolcapone Alone and in Combination With Oxaliplatin in Patients With Relapsed or Refractory Neuroblastoma
A Phase I Trial of Tolcapone Alone and in Combination With Oxaliplatin in Patients With Relapsed or Refractory Neuroblastoma
Enrollment Status: Terminated
Publish Date: August 06, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.
Enrollment Status: Completed
Publish Date: August 06, 2024
Intervention Type: Drug
Study Drugs: Nifurtimox, Cyclophosphamide, Topotecan
Study Phase: Phase 2
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
A Phase I Trial of Temsirolimus (CCI-779, Pfizer, Inc.) in Combination With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients
Enrollment Status: Terminated
Publish Date: August 05, 2019
Intervention Type: Drug
View 8 Less Clinical Trials

20 Total Publications

Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trial.
Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trial.
Journal: EClinicalMedicine
Published: February 04, 2025
Similar Doctors
Payal C. Desai
Elite in Sickle Cell Disease
Dr. Payal C. Desai
Hematology
Elite in Sickle Cell Disease
Dr. Payal C. Desai
Hematology

Atrium Health Levine Cancer Institute

1021 Morehead Medical Drive, 
Charlotte, NC 
 (20.8 miles away)
980-442-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Payal Desai is a Hematologist in Charlotte, North Carolina. Dr. Desai is rated as an Elite provider by MediFind in the treatment of Sickle Cell Disease. Her top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Congenital Hemolytic Anemia, Hemolytic Anemia, and Bone Marrow Aspiration. Dr. Desai is currently accepting new patients.

Elite in Sickle Cell Disease
Dr. Ifeyinwa M. Osunkwo
Pediatrics | Hematology | Oncology
Elite in Sickle Cell Disease
Dr. Ifeyinwa M. Osunkwo
Pediatrics | Hematology | Oncology
201 E Grover St, 
Shelby, NC 
 (53.5 miles away)
980-487-2600
Languages Spoken:
English
See accepted insurances

Ifeyinwa Osunkwo is a Pediatrics specialist and a Hematologist in Shelby, North Carolina. Dr. Osunkwo is rated as a Distinguished provider by MediFind in the treatment of Sickle Cell Disease. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, and Hemolytic Anemia.

Lilian Harris
Distinguished in Sickle Cell Disease
Dr. Lilian Harris
Oncology | Hematology
Distinguished in Sickle Cell Disease
Dr. Lilian Harris
Oncology | Hematology

Novant Health Cancer Institute - Mint Hill

8201 Healthcare Loop, Suite 201, 
Charlotte, NC 
 (15.1 miles away)
980-302-2000
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lilian Harris is a Hematologist and an Oncologist in Charlotte, North Carolina. Dr. Harris has been practicing medicine for over 21 years and is rated as an Advanced provider by MediFind in the treatment of Sickle Cell Disease. Her top areas of expertise are Sickle Cell Disease, Hemoglobin SC Disease, Thrombocytopenia, and Non-Hodgkin Lymphoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oesterheld's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile